A Novel Agent Tasquinimod Demonstrates a Potent Anti-Tumor Activity in Pre-Clinical Models of Multiple Myeloma

被引：3
|
作者：
Ramachandran, Indu R. [1 ]
Lin, Cindy [1 ]
Chase, Tess [2 ]
Gabrilovich, Dmitry [1 ]
Nefedova, Yulia [1 ]
机构：
[1] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA
[2] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
10.1182/blood.V124.21.5729.5729
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] A novel HSP70 inhibitor demonstrates potent anti-myeloma activity
    Bailey, Charvann K.
    Budina, Anna
    Murphy, Maureen
    Nefedova, Yulia
    CANCER RESEARCH, 2015, 75
  • [42] The histone deacetylase inhibitor UCL67022 has potent activity in multiple myeloma and non-Hodgkin lymphoma pre-clinical models
    Maharaj, Lenushka
    Marson, Charles M.
    Middleton, Brian J.
    Rioja, Alf S.
    Perry, Jackie
    Oakervee, Heather
    Cavenagh, Jamie
    Joel, Simon P.
    Popat, Rakesh
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 163 (01) : 135 - 139
  • [43] BCMA-Targeted, Hypoimmune Allogeneic CAR T Cells Exhibit Potent Anti-Tumor Activity Together with the Ability to Evade Innate and Adaptive Immune Rejection in Pre-Clinical Tumor Models
    Kinder, Jeremy M.
    Athena-Estrada, Chanel
    Malik, Danyal
    Hu, Xiaomeng
    Lamba, Meghan
    Young, Chi
    Van Hoeven, Neal
    Granger, Brian
    Chaturvedi, Vandana
    Liang, Ouwen
    Moreno, Jesus
    Lampano, Aaron
    Zipp, Garrett
    Johnson, Adam
    Fry, Terry
    Schrepfer, Sonja
    Foster, Aaron
    BLOOD, 2022, 140 : 7120 - 7121
  • [44] AO-176, a Differentiated Clinical-Stage Anti-CD47 Antibody, Demonstrates Potent Anti-Tumor Activity across Multiple Preclinical Models of B Cell Neoplasms
    Wilson, William Casey
    Richards, John O.
    Andrejeva, Gabriela
    Capoccia, Benjamin J.
    Puro, Robyn J.
    Donio, Mike J.
    Hiebsch, Ronald R.
    Kashyap, Arun K.
    Pereira, Daniel S.
    BLOOD, 2021, 138
  • [45] BSC2118, a novel proteasome inhibitor with in vitro anti-tumor activity in multiple myeloma
    Sterz, J.
    Metzler, I. V.
    Kuckelkorn, U.
    Braun, H. A.
    Rotzer, S.
    Kaiser, M.
    Fleissner, C.
    Heider, U.
    Kloetzel, P. M.
    Sezer, O.
    Jakob, C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 152 - 152
  • [46] A Novel ICAM-1/CD54 Antibody Identified By Phage Display with Potent Pre-Clinical Anti-Myeloma Activity
    Klausz, Katja
    Burger, Renate
    Kellner, Christian
    Peipp, Matthias
    Gramatzki, Martin
    BLOOD, 2014, 124 (21)
  • [47] Activity of Orally Available CBP/p300 Degraders in Pre-Clinical Models of Multiple Myeloma
    Tiwari, Praveen Kumar
    Harrison, Drew A.
    Ojeda, Samuel
    Kawale, Ajinkya S.
    Doda, Sai Reddy
    Uannam, Raghu
    Karakyriakou, Barbara
    Koglin, Ann-Sophie
    Rizvi, Sarah
    Ott, Christopher J.
    BLOOD, 2024, 144 : 2795 - 2795
  • [48] SYSTEM FOR PRE-CLINICAL STUDY AND PREDICTION OF THE THERAPEUTIC EFFECT OF ANTI-TUMOR DRUGS
    KARAIVANOVA, MH
    DOKLADI NA BOLGARSKATA AKADEMIYA NA NAUKITE, 1983, 36 (02): : 293 - 296
  • [49] IMMUNE ANTI-TUMOR RESPONSE IN THE PRE-CLINICAL PERIOD OF LUNG-CANCER
    KOTLAR, HK
    SANNER, T
    EKER, P
    PIHL, A
    ORJASAETER, H
    HARVEI, S
    THEODORSEN, L
    JELLUM, E
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1982, 18 (03): : 317 - 319
  • [50] Anti-tumor efficacy and pre-clinical immunogenicity of IFNα2a-NGR
    Zhang, Baolai
    Gao, Bei
    Dong, Shuhong
    Zhang, Yingqi
    Wu, Yongjie
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2011, 60 (01) : 73 - 78
12345